83-5965-05　CD4, Clenoliximab Biosimilar 1mg　591757

特徴

• Clenoliximab Biosimilar uses the same protein sequences as the therapeutic antibody clenoliximab.
• Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator.
• It has been investigated for the treatment of rheumatoid arthritis.
• Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) that binds specifically to the CD4 receptor present on T-lympocytes (Helper T lymphocytes).
• CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA).
• Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lympocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lympocytes in circulation.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Clenoliximab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.